January 30, 2013
Pharmaceutical company Merck (NYSE: MRK ) is often seen as a solid defensive play for investors looking for dividend-paying health care stocks. While this is one of the largest drugmakers in the world, there are still many issues that investors need to watch. In this video, health care analyst Max Macaluso runs down three areas investors must track in 2013.
For nearly 100 years, Merck's cutting-edge research has led to a number of medical breakthroughs. Today, however, this pharma stalwart is staring down a steep patent cliff and facing generic competition for its top-selling drug. For more detailed information, make sure you take a look at our brand new premium research report today. Our senior biotech analyst Brian Orelli, Ph.D., walks you through both the opportunities and threats facing Merck, and the report comes with a full 12 months of updates. Claim your copy now by clicking here.